Management ChangeJun 10, 2026, 04:32 PM
Vir Biotechnology Appoints Timothy Coughlin to Board, Audit Chair
AI Summary
Vir Biotechnology's Board of Directors increased its size from seven to eight members and appointed Timothy Coughlin, CPA, as a Class III director, effective immediately. Mr. Coughlin will serve until the 2028 annual meeting and also assume the role of Chair of the Audit Committee. As a non-employee director, he will receive standard cash and equity compensation, including stock options and restricted stock units, and has entered into a standard indemnity agreement with the company.
Key Highlights
- Vir Biotechnology's Board increased its size from seven to eight members.
- Timothy Coughlin, CPA, was appointed as a Class III director.
- Mr. Coughlin will serve on the Board until the Company’s 2028 annual meeting of stockholders.
- Mr. Coughlin was also appointed as Chair of the Audit Committee of the Board.
- As a non-employee director, Mr. Coughlin will receive standard cash and equity compensation.
- Compensation includes stock option and restricted stock unit awards under the 2019 Equity Incentive Plan.
- The company entered into a standard indemnity agreement with Mr. Coughlin.
- There are no related party transactions between the Company and Mr. Coughlin.
Price Impact
More from VIR